공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 MRSA 치료제 시장

MRSA Drugs

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품 코드 997512
페이지 정보 영문 179 Pages
가격
US $ 4,950 ₩ 5,625,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 16,875,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 MRSA 치료제 시장 MRSA Drugs
발행일 : 2021년 04월 페이지 정보 : 영문 179 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 MRSA 치료제 시장 규모는 분석기간(2020-2027년)에 3%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 31억 달러에서 2027년에는 38억 달러에 달할 것으로 예측됩니다.

본 보고서에서 분석한 부문 중 하나인 리포펩타이드(Lipopeptide)는 분석기간 중 1.7%의 CAGR을 나타내고, 12억 달러에 달할 전망입니다.

세계의 MRSA 치료제(MRSA Drugs) 시장에 대해 조사했으며, 시장 점유율, COVID-19의 영향, 동향 및 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 예

  • Absynth Biologics
  • Allergan PLC
  • AmpliPhi Biosciences Corporation
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Baxter International, Inc.
  • Cempra, Inc.
  • CrystalGenomics Inc.
  • Debiopharm Group
  • Galapagos NV
  • GlaxoSmithKline plc
  • Innovation Pharmaceuticals Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lytix Biopharma AS
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.
  • Nabriva Therapeutics US, Inc.
  • NovaDigm Therapeutics, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • R-Pharm-US LLC
  • Savara Inc.
  • Sealife PHARMA GMBH
  • Sequella, Inc.
  • The Medicines Company
  • Theravance Biopharma, Inc.
  • XBiotech Inc.

목차

I. 조사 방법

II. 개요

  • 시장 개요
    • 인플루언서 시장 인사이트
    • 세계 시장 궤적
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기침체
  • 주요 기업
  • 동향 및 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 개요 : 41개사
LSH 21.04.08

Abstract:

Global MRSA Drugs Market to Reach $3.8 Billion by 2027

Amid the COVID-19 crisis, the global market for MRSA Drugs estimated at US$3.1 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 3% over the analysis period 2020-2027. Lipopeptide, one of the segments analyzed in the report, is projected to record a 1.7% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Oxazolidinone segment is readjusted to a revised 4.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $905.2 Million, While China is Forecast to Grow at 2.9% CAGR

The MRSA Drugs market in the U.S. is estimated at US$905.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$678.6 Million by the year 2027 trailing a CAGR of 2.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 2.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Cephalosporin Segment to Record 4.3% CAGR

In the global Cephalosporin segment, USA, Canada, Japan, China and Europe will drive the 4.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$359.3 Million in the year 2020 will reach a projected size of US$487.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$424.6 Million by the year 2027.

Select Competitors (Total 41 Featured) -

  • Absynth Biologics
  • Allergan PLC
  • AmpliPhi Biosciences Corporation
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Baxter International, Inc.
  • Cempra, Inc.
  • CrystalGenomics Inc.
  • Debiopharm Group
  • Galapagos NV
  • GlaxoSmithKline plc
  • Innovation Pharmaceuticals Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lytix Biopharma AS
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.
  • Nabriva Therapeutics US, Inc.
  • NovaDigm Therapeutics, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • R-Pharm-US LLC
  • Savara Inc.
  • Sealife PHARMA GMBH
  • Sequella, Inc.
  • The Medicines Company
  • Theravance Biopharma, Inc.
  • XBiotech Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Lipopeptide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Lipopeptide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Lipopeptide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Oxazolidinone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Oxazolidinone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Oxazolidinone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 37: Japan Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 40: Japan Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 43: China Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 46: China Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 49: Europe Current & Future Analysis for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 58: France Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 61: France Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 64: Germany Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 67: Germany Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 70: Italy Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 73: Italy Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 76: UK Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 79: UK Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 85: Rest of Europe Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 88: Asia-Pacific Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 91: Asia-Pacific Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 94: Rest of World Current & Future Analysis for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for MRSA Drugs by Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline and Other Drug Classes for the Years 2012, 2020 & 2027
    • TABLE 97: Rest of World Current & Future Analysis for MRSA Drugs by Route Of Administration - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of World Historic Review for MRSA Drugs by Route Of Administration - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of World 15-Year Perspective for MRSA Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 41
Back to Top
전화 문의
F A Q